Abstract
Previous reports have described the phenotypic and functional properties of monotypic late stage B cells in the blood of patients with multiple myeloma and have speculated that these B cells represent a malignant circulating component of myeloma. Here we show that blood B cells have IgH rearrangements identical to those expressed by the bone marrow plasma cells by using Ig Fingerprint and Allele-Specific Oligomer (ASO) polymerase chain reaction (PCR) methods. DNA from purified blood B ceils and bone marrow plasma cells taken at the same time, and blood B cells taken at subsequent patient visits was amplified using consensus IgH primers, or ASO primers. In 10/16 patients, a single IgH rearrangement was amplified from the bone marrow plasma cells. In all 10 of those patients the same clonotypic rearrangement was amplified from the purified blood B cells. The relationship of these clonal blood B cells to the malignant bone marrow plasma cells remains undetermined
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bergsagel DE (1990) Treatment of plasma cell myeloma. Ann Rev Med 30: 431–3
Palmer M, Belch A, Hanson J, Brox L (1989) Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br J Cancer 59: 110–2
Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, Willan A (1988) A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding myeloma patients. Br J Cancer 57: 94–9
Griepp PR (1992) Advances in the diagnosis and management of myeloma. Sem Hematol 29: 24–45
Barlogie B, Gahrton G (1991) Bone arrow transplantation in multiple myeloma. Bone Marrow Transplant 7: 71–9
Harousseau JL, Milpied N, Laporte JP, et al. (1992) Double–intensive therapy in high-risk multiple myeloma. Blood 79: 2827–33
Barlogie B, Epstein J, Selvanayagam P, Alexanian R (1989) Plasma cell myeloma — new biological insights and advances in therapy. Blood 73: 865–79
Sonneveld P, Durie BGM, Lokhorst HM, et al. (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255–9
Salmon SE, Dalton WS, Grogan TM, et al. (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44–50
Dalton WS, Grogan TM, Meltzer PS, et al. (1989) Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–24
Pilarski LM, Mant MM, Belch AR (1993) Circulating, monoclonal, multi-drag resistant B cells may comprise the malignant stem cells population in multiple myeloma. In: Dammaco F (ed) Frontiers in Immunology and Cancer Research, (in press)
Pilarski LM, Belch AJ (1994) Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 83: 724–36
Pilarski LM, Jensen GS (1992) Monoclonal circulating B cells in multiple myeloma: A continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 6: 297–322
Jensen GS, Mant MJ, Belch AJ, Berensen JR, Ruether BA, Pilarski LM (1991) Selective expression of CD45 isoforms defines CALLA+ monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78: 711–9
Jensen GS, Belch AR, Kherani F, Mant MJ, Ruether BA, Pilarski LM (1992) Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD lib on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand J Immunol 36: 843–53
Pilarski LM, Masellis Smith A, Belch AR, Yang B, Savani RC, Turley EA (1994) RHAMM, a receptor for hyaluronan-mediated motility, on normal lymphocytes, thymocytes and in B cell malignancy: An oncogene in B cell malignancy? Leuk Lymphoma (in press)
Jensen GS, Belch AR, Mailt MJ, Ruether BA, Yacyshyn BR, Pilarski LM (1992) Expression of multiple beta-1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 43: 29–36
Hardwick C, Hoare K, Owens R, et al. (1992) Molecular cloning of a novel hyaluronan receptor that mediates tumor motility. J Cell Biol 117: 1343–50
Turley EA, Austin L, Vandligt K, Clary C (1991) Hyaluronan and a cell associated hyaluronan binding protein regulate the locomotion of ras-transformed cells. J Cell Biol 112: 1041–7
Turley EA, Belch AR, Poppema S, Pilarski LM (1993) Expression and function of a receptor for hyaluronan-mediated motility (RHAMM) on normal and malignant B lymphocytes. Blood 81:446–53
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bergsagel, P.L., Masellis Smith, A., Belch, A.R., Pilarski, L.M. (1995). The Blood B-Cells and Borie Marrow Plasma Cells in Patients with Multiple Myeloma Share Identical IgH Rearrangements. In: Potter, M., Melchers, F. (eds) Mechanisms in B-Cell Neoplasia 1994. Current Topics in Microbiology and Immunology, vol 194. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79275-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-79275-5_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79277-9
Online ISBN: 978-3-642-79275-5
eBook Packages: Springer Book Archive